Cargando…

LC–MS-Based Qualitative Analysis and Pharmacokinetic Integration Network Pharmacology Strategy Reveals the Mechanism of Phlomis brevidentata H.W.Li Treatment of Pneumonia

[Image: see text] Phlomis brevidentata H.W.Li Radix (PbR) is a rare traditional Tibetan medicine, and it is widely used in the Chinese Tibetan region for the treatment of pharyngitis, pneumonia, and so forth. Nevertheless, there is very little research on its modern pharmacy, and the active ingredie...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chenning, Liu, Chuanxin, Qu, Yuxia, Cao, Yijia, Liu, Runhua, Sun, Yu, Nyima, Tsring, Zhang, Shuofeng, Sun, Yikun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893793/
https://www.ncbi.nlm.nih.gov/pubmed/33623855
http://dx.doi.org/10.1021/acsomega.0c06201
_version_ 1783653119016566784
author Zhang, Chenning
Liu, Chuanxin
Qu, Yuxia
Cao, Yijia
Liu, Runhua
Sun, Yu
Nyima, Tsring
Zhang, Shuofeng
Sun, Yikun
author_facet Zhang, Chenning
Liu, Chuanxin
Qu, Yuxia
Cao, Yijia
Liu, Runhua
Sun, Yu
Nyima, Tsring
Zhang, Shuofeng
Sun, Yikun
author_sort Zhang, Chenning
collection PubMed
description [Image: see text] Phlomis brevidentata H.W.Li Radix (PbR) is a rare traditional Tibetan medicine, and it is widely used in the Chinese Tibetan region for the treatment of pharyngitis, pneumonia, and so forth. Nevertheless, there is very little research on its modern pharmacy, and the active ingredients and mechanisms against these diseases remain unknown. In this study, we employed the qualitative analysis and pharmacokinetic based on LC–MS technology and network pharmacology to explore the active ingredients and mechanisms of PbR for treatment of pneumonia. Ultraperformance liquid chromatography coupled with time-of-flight mass spectrometry (UPLC-Q-TOF/MS) methodology was applied to identify the chemical composition of PbR. Meanwhile, a UPLC-MS/MS method was developed to quantify three active constituents (sesamoside, shanzhiside methyl ester, and barlerin) in rat plasma for the pharmacokinetic analysis after oral administration of PbR. Finally, in order to clarify the anti-pneumonia mechanism of this rare Tibetan medicine, a comprehensive network pharmacology strategy was applied. As a result, a total of 23 compounds were identified in PbR, including 14 iridoid glycosides, 7 phenylethanoid glycosides, and 2 other kinds of compounds. Pharmacokinetic studies have shown that the three compounds exhibit extremely similar pharmacokinetic characteristics, possibly due to their highly analogous chemical structure. We speculate that the iridoid glycosides may be the main active component in PbR. Then, the three iridoid glycoside constituents absorbed into blood were subjected to network pharmacology analysis for treatment of pneumonia. Compound-target-disease, gene ontology bioanalysis, KEGG pathway, and other network pharmacology analysis methods were applied to reveal that five main targets of the three iridoid glycosides, namely, GAPDH, ALB, MAPK1, AKT1, and EGFR, were significant in the regulation of the above bioprocesses and pathways. These results provide a basis for elucidating the bioactive compounds and the pharmacological mechanisms of P. brevidentata H.W.Li radix under clinical applications.
format Online
Article
Text
id pubmed-7893793
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-78937932021-02-22 LC–MS-Based Qualitative Analysis and Pharmacokinetic Integration Network Pharmacology Strategy Reveals the Mechanism of Phlomis brevidentata H.W.Li Treatment of Pneumonia Zhang, Chenning Liu, Chuanxin Qu, Yuxia Cao, Yijia Liu, Runhua Sun, Yu Nyima, Tsring Zhang, Shuofeng Sun, Yikun ACS Omega [Image: see text] Phlomis brevidentata H.W.Li Radix (PbR) is a rare traditional Tibetan medicine, and it is widely used in the Chinese Tibetan region for the treatment of pharyngitis, pneumonia, and so forth. Nevertheless, there is very little research on its modern pharmacy, and the active ingredients and mechanisms against these diseases remain unknown. In this study, we employed the qualitative analysis and pharmacokinetic based on LC–MS technology and network pharmacology to explore the active ingredients and mechanisms of PbR for treatment of pneumonia. Ultraperformance liquid chromatography coupled with time-of-flight mass spectrometry (UPLC-Q-TOF/MS) methodology was applied to identify the chemical composition of PbR. Meanwhile, a UPLC-MS/MS method was developed to quantify three active constituents (sesamoside, shanzhiside methyl ester, and barlerin) in rat plasma for the pharmacokinetic analysis after oral administration of PbR. Finally, in order to clarify the anti-pneumonia mechanism of this rare Tibetan medicine, a comprehensive network pharmacology strategy was applied. As a result, a total of 23 compounds were identified in PbR, including 14 iridoid glycosides, 7 phenylethanoid glycosides, and 2 other kinds of compounds. Pharmacokinetic studies have shown that the three compounds exhibit extremely similar pharmacokinetic characteristics, possibly due to their highly analogous chemical structure. We speculate that the iridoid glycosides may be the main active component in PbR. Then, the three iridoid glycoside constituents absorbed into blood were subjected to network pharmacology analysis for treatment of pneumonia. Compound-target-disease, gene ontology bioanalysis, KEGG pathway, and other network pharmacology analysis methods were applied to reveal that five main targets of the three iridoid glycosides, namely, GAPDH, ALB, MAPK1, AKT1, and EGFR, were significant in the regulation of the above bioprocesses and pathways. These results provide a basis for elucidating the bioactive compounds and the pharmacological mechanisms of P. brevidentata H.W.Li radix under clinical applications. American Chemical Society 2021-02-01 /pmc/articles/PMC7893793/ /pubmed/33623855 http://dx.doi.org/10.1021/acsomega.0c06201 Text en © 2021 The Authors. Published by American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.
spellingShingle Zhang, Chenning
Liu, Chuanxin
Qu, Yuxia
Cao, Yijia
Liu, Runhua
Sun, Yu
Nyima, Tsring
Zhang, Shuofeng
Sun, Yikun
LC–MS-Based Qualitative Analysis and Pharmacokinetic Integration Network Pharmacology Strategy Reveals the Mechanism of Phlomis brevidentata H.W.Li Treatment of Pneumonia
title LC–MS-Based Qualitative Analysis and Pharmacokinetic Integration Network Pharmacology Strategy Reveals the Mechanism of Phlomis brevidentata H.W.Li Treatment of Pneumonia
title_full LC–MS-Based Qualitative Analysis and Pharmacokinetic Integration Network Pharmacology Strategy Reveals the Mechanism of Phlomis brevidentata H.W.Li Treatment of Pneumonia
title_fullStr LC–MS-Based Qualitative Analysis and Pharmacokinetic Integration Network Pharmacology Strategy Reveals the Mechanism of Phlomis brevidentata H.W.Li Treatment of Pneumonia
title_full_unstemmed LC–MS-Based Qualitative Analysis and Pharmacokinetic Integration Network Pharmacology Strategy Reveals the Mechanism of Phlomis brevidentata H.W.Li Treatment of Pneumonia
title_short LC–MS-Based Qualitative Analysis and Pharmacokinetic Integration Network Pharmacology Strategy Reveals the Mechanism of Phlomis brevidentata H.W.Li Treatment of Pneumonia
title_sort lc–ms-based qualitative analysis and pharmacokinetic integration network pharmacology strategy reveals the mechanism of phlomis brevidentata h.w.li treatment of pneumonia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893793/
https://www.ncbi.nlm.nih.gov/pubmed/33623855
http://dx.doi.org/10.1021/acsomega.0c06201
work_keys_str_mv AT zhangchenning lcmsbasedqualitativeanalysisandpharmacokineticintegrationnetworkpharmacologystrategyrevealsthemechanismofphlomisbrevidentatahwlitreatmentofpneumonia
AT liuchuanxin lcmsbasedqualitativeanalysisandpharmacokineticintegrationnetworkpharmacologystrategyrevealsthemechanismofphlomisbrevidentatahwlitreatmentofpneumonia
AT quyuxia lcmsbasedqualitativeanalysisandpharmacokineticintegrationnetworkpharmacologystrategyrevealsthemechanismofphlomisbrevidentatahwlitreatmentofpneumonia
AT caoyijia lcmsbasedqualitativeanalysisandpharmacokineticintegrationnetworkpharmacologystrategyrevealsthemechanismofphlomisbrevidentatahwlitreatmentofpneumonia
AT liurunhua lcmsbasedqualitativeanalysisandpharmacokineticintegrationnetworkpharmacologystrategyrevealsthemechanismofphlomisbrevidentatahwlitreatmentofpneumonia
AT sunyu lcmsbasedqualitativeanalysisandpharmacokineticintegrationnetworkpharmacologystrategyrevealsthemechanismofphlomisbrevidentatahwlitreatmentofpneumonia
AT nyimatsring lcmsbasedqualitativeanalysisandpharmacokineticintegrationnetworkpharmacologystrategyrevealsthemechanismofphlomisbrevidentatahwlitreatmentofpneumonia
AT zhangshuofeng lcmsbasedqualitativeanalysisandpharmacokineticintegrationnetworkpharmacologystrategyrevealsthemechanismofphlomisbrevidentatahwlitreatmentofpneumonia
AT sunyikun lcmsbasedqualitativeanalysisandpharmacokineticintegrationnetworkpharmacologystrategyrevealsthemechanismofphlomisbrevidentatahwlitreatmentofpneumonia